Implementing a novel method to estimate the "Burden of Therapy" (BOTh) for patients with metastatic pancreatic cancer treated with gemcitabine plus afatinib vs. gemcitabine in the AIO ACCEPT trial.

Michael Haas,Ayad K AbdulAhad,Robert Snijder,Dirk Waldschmidt,Michael Stahl,Anke Reinacher-Schick,J Freiberg-Richter,Florian Kaiser,Stephan Kanzler,Norbert Frickhofen,Thomas Seufferlein,Tobias Dechow,Rolf Mahlberg,Peter Malfertheiner,Gerald Illerhaus,Stefan Kubicka,Swantje Held,Stefan Boeck,Michael von Bergwelt-Baildon,Volker Heinemann

Implementing a novel method to estimate the "Burden of Therapy" (BOTh) for patients with metastatic pancreatic cancer treated with gemcitabine plus afatinib vs. gemcitabine in the AIO ACCEPT trial.

2020

e16786Background: The phase II ACCEPT trial included 119 patients (pts) with histologically proven pancreatic cancer without any previous systemic treatment for metastatic disease. Pts were randomi...

Keywords:

Oncology
Metastatic pancreatic cancer
Gemcitabine
Internal medicine
Pathology
Medicine
Afatinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations